Uncategorized Archives - BioMedWire (BMW)

WednesdayJun 24, 2026 11:15 am

VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline

VERAXA Biotech has reported new in vitro proof-of-concept data supporting its BiTAC-ADC technology, demonstrating selective activity against cancer cells while sparing healthy cells in early testing. The company is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO International Convention 2026. VERAXA’s proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells. The company maintains a diversified oncology pipeline of antibody-based formats including antibody-drug conjugates (“ADCs”), T-cell engagers (“TCEs”), and other antibody-based formats. VERAXA recently began trading on the NASDAQ Capital Market under the…

WednesdayJun 24, 2026 10:30 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF): Cancer Nanomedicine Enters a New Generation

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. Cancer nanomedicine is emerging from an early period of skepticism, with more than 20 approved formulations now improving therapeutic index and patient quality of life during treatment Onco-Innovations’ lead drug candidate, ONC010, pairs a small-molecule PNKP inhibitor with a polymer nanodelivery system designed to extend circulation, increase drug retention in tumor, and improve tolerability Recent manufacturing updates, including kilogram-scale precursor production and a proposed Nanosoft Polymers collaboration, point to a sharpening focus on scalability, reproducibility, and regulatory readiness ahead of first-in-human studies For decades, chemotherapy has…

TuesdayJun 23, 2026 10:30 am

The $410 Billion Drug Delivery Revolution: Why Drug Delivery May Be the Next Major Frontier in Oncology Innovation

The rapidly expanding nanomedicine and advanced drug-delivery market is attracting growing attention as pharmaceutical companies seek ways to improve therapeutic performance without relying solely on costly new drug discovery programs. By addressing challenges such as poor bioavailability, inconsistent pharmacokinetics and limited tumor penetration, nanotechnology-based delivery systems may unlock additional value from existing oncology drugs. Oncotelic Therapeutics’ Deciparticle(TM) platform and Sapu003 program illustrate how innovative drug delivery approaches could help reshape the future of cancer treatment. The search for new cancer therapies has traditionally focused on discovering entirely new drug candidates. While this approach has produced important breakthroughs, it is also…

MondayJun 22, 2026 11:15 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Targets a $393 Billion Heart Disease Problem with Epigenetics and AI

For cardiovascular conditions, annual health care costs are forecasted to increase from $393 billion in 2020 to $1.4 trillion by 2050, almost quadrupling in size. What makes Cardio Diagnostics' approach distinct, and what gives the company a defensible clinical position, is its ability to detect coronary heart disease earlier and with high sensitivity. The company's recent commercial and regulatory milestones give additional shape to the investment thesis. Heart disease has held the grim distinction of being the leading cause of death in the United States for decades, and despite advances in medicine, the problem is getting worse, not better. According…

MondayJun 22, 2026 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Launches Study Focused on Testing Proprietary Patch Capable of Generating On-Demand 12-Lead ECG for Ischemia Detection

The seriousness of coronary artery disease continues to intensify as populations age and cardiovascular risk factors become more common. HeartBeam announced the launch of a pilot study focused on evaluating its on-demand 12-lead ECG patch in detecting coronary artery disease and inadequate blood flow and oxygen supply to tissue, or ischemia. The study represents a significant step in the development of the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (“MCT”) markets. Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of…

ThursdayJun 18, 2026 10:30 am

Earth Science Tech Inc. (ETST) Signals Strong Confidence with Aggressive Q1 Share Buybacks

Aggressive repurchase of its own stock by Earth Science Tech, a growing holding company focused on various aspects of the healthcare industry, reflects management’s growing internal confidence in the company’s future trajectory. Over 3 million shares of common stock have been repurchased in current fiscal quarter, a significant acceleration in buybacks. Reduction in share dilution can consolidate existing equity and potentially boost earnings per share (“EPS”). Earth Science Tech (OTC: ETST) is capturing the attention of the micro-cap market following a significant acceleration of its share repurchase program. Recent market data indicates that the company is aggressively buying back its own…

ThursdayJun 18, 2026 9:00 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Launches Lead Commercial Software Intox AI(TM) for Multiple Forms of Intoxication Detection

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. The platform is designed to detect cocaine, cannabis, alcohol, narcotics, psychedelics, and human fatigue using voice analysis and artificial intelligence. MindBio is preparing to deploy the software through Edge AI kiosk systems targeted at safety-critical industries. The company is pursuing commercialization opportunities in mining, aviation, construction, transportation, and law enforcement markets. MindBio’s technology offers a non-invasive and affordable alternative to traditional drug and alcohol testing methods. The launch represents a key step in the company’s transition from research and clinical development toward commercial implementation. MindBio Therapeutics…

TuesdayJun 16, 2026 11:15 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Working to Help Employers Tackle Cardiovascular Risk, Healthcare Costs

Cardiovascular disease remains one of the most expensive health conditions in the United States. Cardio Diagnostics announced plans to participate in four national benefits conferences during June. The company has developed a suite of solutions designed to provide earlier identification of cardiovascular risk and enable more targeted interventions and preventive care. A single heart attack or major cardiovascular event can have consequences that extend far beyond a patient’s health, affecting employers, insurers and healthcare systems through higher medical costs, lost productivity and long-term care expenses. As cardiovascular disease continues to drive a significant share of healthcare spending, organizations responsible for…

TuesdayJun 16, 2026 10:00 am

How Authorities are Protecting Public Health During the FIFA World Cup

The FIFA World Cup started on June 11 and will end on July 19. 48 national teams are taking part, and this is an extra 16 teams when compared to the number of national teams that participated in the last edition that took place in Qatar in 2022. 100 matches are scheduled to be played across the U.S., Mexico and Canada. An international sporting event of this magnitude presents a major challenge to public health planners, and authorities have been working fervently to put in place measures geared at keeping infectious disease risks at bay during the tournament. We discuss…

FridayJun 12, 2026 9:45 am

Earth Science Tech Inc. (ETST) Reports Transformational Fiscal Year as Share Repurchases and Healthcare Expansion Shape Growth Strategy

Earth Science Tech, a growing holding company focused on various aspects of the healthcare industry, reported a series of operational milestones in its fiscal year ended March 31, 2026, highlighted by expansion across its healthcare platform and continued cash-flow generation. Earth Science Tech repurchased and retired more than 6.9 million shares of common stock since fiscal Q1 2026, underscoring management’s focus on reducing share dilution in support of shareholder value. Key operating businesses, including DOConsultation, Villas Health and MOC Teledoc, are now cash-flow positive. Peaks Curative surpassed $2 million in revenue during the first week of fiscal Q4 2026, reflecting…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF): Cancer Nanomedicine Enters a New Generation

The $410 Billion Drug Delivery Revolution: Why Drug Delivery May Be the Next Major Frontier in Oncology Innovation

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Targets a $393 Billion Heart Disease Problem with Epigenetics and AI

HeartBeam Inc. (NASDAQ: BEAT) Launches Study Focused on Testing Proprietary Patch Capable of Generating On-Demand 12-Lead ECG for Ischemia Detection

Earth Science Tech Inc. (ETST) Signals Strong Confidence with Aggressive Q1 Share Buybacks

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Launches Lead Commercial Software Intox AI(TM) for Multiple Forms of Intoxication Detection

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Working to Help Employers Tackle Cardiovascular Risk, Healthcare Costs

How Authorities are Protecting Public Health During the FIFA World Cup

Earth Science Tech Inc. (ETST) Reports Transformational Fiscal Year as Share Repurchases and Healthcare Expansion Shape Growth Strategy

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search